Enoxaparin and Unfractionated Heparin in Acute Coronary Syndromes Without ST-segment Elevation

Marc Cohen; Elliott M. Antman

doi:10.1055/s-0037-1613326

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2002; 88(05): 884-886
DOI: 10.1055/s-0037-1613326

Letters to the Editor

Schattauer GmbH

Enoxaparin and Unfractionated Heparin in Acute Coronary Syndromes Without ST-segment Elevation

Marc Cohen

¹Division of Cardiology, MCP-Hahnemann University School of Medicine, Philadelphia, Pennsylvania, USA

,

Elliott M. Antman

²Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA

› Author Affiliations

Abstract

Full Text

References

References
1 Salvioni A, Casilli F, Assanelli E, Grazi M, Marenzi G, Guazzi MD. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation. Thromb Haemost 2001; 86: 991-4.
2 Gurfinkel E, Duronto E, Colorio C, Bozovich G, Cohen M, Mautner B. Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin. J Thromb Thrombolysis 1999; 08: 227-32.
3 Borja J, Olivella P. Enoxaparin and unfractionated heparin in acute coronary syndromes without ST-segment elevation [letter]. Thromb Haemost 2002; 87: 538.
4 Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braun-wald E. for the TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601.
5 Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
6 Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith 3rd EE, Steward DE, Theroux P, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith Jr SC. ACC/AH A guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000; 36: 970-1062.
7 Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E. for the TIMI IIB and ESSENCE Investigators. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002; 23: 308-14.
8 Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. for the TIMI 11B-ESSENCE Investigators. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-8.
9 The ASSENT-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
10 Michalis LK, Katsouras CS, Papamichael MD, Adamides K, Naka KK, Goudevenos J, Sideris DA. Enoxaparin versus tinzaparin in non-ST-segment elevation myocardial infarction. Eur Heart J 2001; 22 suppl 1-779.
11 Holdright D, Patel D, Cunningham D, Thomas R, Hubbard W, Hendry G, Sutton G, Fox K. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994; 24: 39-45.
12 Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 811-5.
13 Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996; 94: 911-21.
14 The Direct Thrombin Inhibitor Trialists’ Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a metaanalysis based on individual patients’ data. Lancet 2002; 359: 294-302.
15 Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61-8.
16 The FRAXIS Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non Q wave myocardial infarction: FRAXIS (Fraxiparine in Acute Ischaemic Syndrome). Eur Heart J 1999; 20: 1553-62.
17 Bozovich GE, Gurfinkel EP, Antman EM, McCabe CH, Mautner B. Superiority of enoxaparin versus unfractionated heparin for unstable angina/ non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. Am Heart J 2000; 140: 637-42.
18 Montalescot G, Drouet L. ARMADA study: a randomized comparison of enoxaparin, dalteparin and unfractionated heparin on markers of cell activation in patients with unstable angina [abstract P3597]. Eur Heart J 2001; 22 suppl ii-iv 663..